% CI #.#-#.# [003]

Related by string. % CI #.#-#.# [002] * : % ON HEAVY . % downside protection . -#.# % [002] . % RETURN SEEN / Cid . ci . CIS . CID : % CI #.#-#.# [006] . % CI #.#-#.# [007] . CI = . confidence interval CI / #.# [010] . #.# [027] . #.# [043] . #.# [031] : #.# ov #-# . Yard Freestyle =-#.# mg dL . #.# Promote sexually / #.# [009] . #.# [022] . #.# [039] : Rs #.# [005] . #.# Advocate promote . #.# ERA * *

Related by context. All words. (Click for frequent words.) 81 % CI #.#-#.# [007] 78 % Confidence Interval 77 confidence interval #.#-#.# 77 % CI #.#-#.# [006] 76 % CI #.#-#.# [008] 76 confidence interval CI 75 p = .# [002] 74 CI #.#-#.# [002] 74 P = .# 73 adjunctive placebo 73 interquartile range 73 CI -#.# 72 nondiabetic patients 72 CI = 72 CR nPR 72 p = NS 72 biochemical relapse 72 hours postdose 71 Median PFS 71 lopinavir r arm 71 Kaplan Meier analysis 71 mL/min/#.# m 2 71 μmol L 71 undetectable HBV DNA 71 achieved ACR# 71 advanced adenoma 70 median PFS 70 mIU ml 70 5-FU/LV 70 â ‰ ¥ 70 preintervention 70 p ≤ 70 Flu Cy 70 postintervention 70 confidence intervals CIs 70 % CI #.#-#.# [002] 70 ALT elevation 70 progression TTP 70 % CI #.#-#.# [001] 70 PSA nadir 69 clodronate 69 amoxicillin clavulanate 69 CC genotype 69 pmol liter 69 MADRS score 69 underwent resection 69 CI #.#-#.# [001] 69 REYATAZ r arm 69 CCyR 69 euthyroid 69 locoregional recurrence 69 posttreatment 69 relapsed MM 69 lowest tertile 69 pmol L 69 HBeAg negative patients 69 mcg albinterferon alfa 2b 69 Operative mortality 69 univariate analysis 69 achieved CCyR 69 KRAS mutations occur 69 tipranavir r 69 P ≤ 69 posttransplant 69 pT3 69 FOLFIRI alone 68 microg 68 comparator arm 68 biochemical recurrence 68 recurrent VTE 68 aOR 68 oxycodone CR 68 antiretroviral naïve 68 aged ≥ 68 nadroparin 68 nonsignificant difference 68 sd = 68 AOR = 68 underwent surgical resection 68 NMIBC 68 HBeAg seroconversion 68 advanced neoplasia 68 seroconverted 68 hip BMD 68 p = #.# [003] 68 Median progression 68 recurrent venous thromboembolism 68 seropositivity 68 FOLFOX4 67 mIU L 67 HIV uninfected 67 Partial Responses 67 invasive carcinomas 67 CR CRu 67 mcg QD 67 mL/min/#.# m2 67 μg L 67 -#.# ± [002] 67 adjunctive ABILIFY 67 nmol l 67 p = #.# [002] 67 QTcF 67 % CI #.#-#.# [004] 67 tolterodine ER 67 mmol l 67 n = 67 #.#ng/ml 67 pg ml 67 mg/m2 dose 67 placebo dexamethasone 67 receiving VICTRELIS 67 nonobese patients 67 placebo p = 67 preoperative PSA 67 hypophosphatemia 67 pg mL 67 nmol liter 67 microbiologically evaluable 67 abacavir lamivudine 67 ertapenem 67 pCR 67 mU liter 67 morphometric vertebral fractures 67 lymphocytosis 67 highest tertile 67 lumbar spine BMD 67 colorectal adenoma 66 operable breast cancer 66 Ishak fibrosis score 66 p = #.# [004] 66 mg p = 66 PREZISTA r arm 66 BARACLUDE ® 66 plus dexamethasone 66 octreotide LAR 66 #mg BID [001] 66 multivariable adjusted 66 receiving ISENTRESS 66 lamivudine monotherapy 66 cGy 66 HBeAg negative 66 CIN2 + 66 oral Hycamtin 66 infliximab monotherapy 66 severe neutropenia 66 DAS# CRP 66 NNT = 66 HbA 1c levels 66 mcg BID 66 ng dL 66 serum concentrations 66 parous women 66 #Gy 66 neurodevelopmental impairment 66 nmol L 66 statistically significant p = 66 tPSA 66 HBeAg 66 MCyR 66 8mg/kg 66 4mg/kg 66 FluCAM arm 66 achieved mucosal healing 66 locoregional 66 p = .# [001] 66 ug dose 66 Folfox 66 complete cytogenetic response 66 PREZISTA ritonavir 66 #.#/#.# mmHg [001] 66 tertile 66 methotrexate monotherapy 66 PASI scores 66 -#.# log# 66 tipranavir ritonavir 66 MBq 66 advanced adenomas 66 Hazard Ratio 66 alanine aminotransferase ALT 66 umol L 66 histological subtype 65 pT2 65 median survivals 65 de novo AML 65 μg mL 65 virologic failure 65 mmHg diastolic 65 experienced virologic failure 65 statistical significance p 65 radiotherapy RT 65 ‰ ¥ 65 log# reduction 65 moderately emetogenic 65 lymphocyte count 65 genotypic resistance 65 placebo PBO 65 baseline LDH 65 creatinine ratio 65 Partial Response 65 patients evaluable 65 LV dysfunction 65 = #.#-#.# 65 stage IIIb IV 65 TPV r 65 g dl 65 anemia hemoglobin 65 detectable HCV RNA 65 NNRTI resistance 65 Thal Dex 65 #mg/day [001] 65 IU ml 65 liver histology 65 leukemia AML 65 ECOG PS 65 mitoxantrone plus 65 leukocyte count 65 μg d 65 clinically evaluable patients 65 rFSH 65 CIMZIA TM certolizumab pegol 65 SGPT 65 MACCE 65 #mg QD [001] 65 Kaplan Meier 65 nmol 65 p = 65 Median survival 65 glycated hemoglobin levels 65 pegylated interferon alfa 2b 65 HIV seronegative 65 response CCyR 65 65 neurologic progression 65 MMSE score 65 underwent liver transplantation 65 VcMP 65 femoral neck BMD 65 antibody titer 65 nulliparous women 65 histologically confirmed 65 MetS 65 flutamide 65 HBeAg positive patients 65 mcg linaclotide 65 HbA1C levels 65 elevated LDH 65 nonpregnant women 65 postmenopausal osteoporotic women 65 deep venous thromboses 64 atazanavir ritonavir 64 resected pancreatic cancer 64 nonmetastatic 64 hepatorenal syndrome 64 -#.# mg dL [002] 64 GnRH agonist 64 odds ratios ORs 64 chemoradiation therapy 64 overt nephropathy 64 LPV r 64 chlorambucil 64 IOP lowering 64 evaluable subjects 64 invasive lobular 64 multivariable analysis 64 rizatriptan 64 tertiles 64 certolizumab 64 ipsilateral stroke 64 generalized edema 64 -#.# log# copies mL 64 neutrophil counts 64 Adjuvant chemotherapy 64 HBeAg positive 64 recurrent glioblastoma multiforme 64 annualized relapse 64 sUA 64 TLUS 64 Hazard Ratio HR 64 mm Hg diastolic 64 doxorubicin docetaxel 64 histologically proven 64 thrombocytopenic 64 Engerix B 64 postop 64 baseline HbA1c 64 external genital lesions 64 mg qd 64 log# copies mL 64 squamous histology 64 TEAEs 64 DAS# remission 64 mU L 64 definite stent thrombosis 64 distant metastasis 64 FOLFOX4 alone 64 baseline Hb 64 affective psychosis 64 leukopenia 64 nonobese 64 endometrial thickness 64 partial remissions 64 XIENCE V PROMUS Stent 64 KRAS mutant tumors 64 EDSS score 64 ug kg 64 salmeterol fluticasone 64 primary patency 64 binary restenosis 64 timepoints 64 Free Survival PFS 64 neoplasias 64 metastatic GIST 64 prospectively defined 64 mmHg systolic 64 univariate analyzes 64 AUC0 64 #.#mg/dL 64 MMSE scores 64 plus methotrexate 64 lispro 64 anagrelide 64 budesonide pMDI 64 virologic breakthrough 64 GH deficiency 64 mitoxantrone 64 plus OBT 64 reinfarction 64 alanine aminotransferase 64 seronegative 64 #mg BID [003] 64 femoral shaft fracture 64 clinically meaningful improvement 64 % CI #.#-#.# [005] 64 mCi 64 nicardipine 64 mg Proellex 64 PSADT 64 specific antigen PSA 64 pegylated liposomal doxorubicin 64 interquartile range IQR 64 Index CDAI 64 Wistar rats 64 mg ustekinumab 64 logistic regression analysis 64 μg liter 64 log# IU mL 64 virologic response 64 non splenectomized 64 nonfatal MI 64 androgen suppression 64 CIN3 64 EDSS scores 63 biopsy Gleason 63 highly emetogenic 63 preoperative chemotherapy 63 adjuvant cisplatin 63 rimonabant #mg 63 peginterferon alfa 2a 63 CI #.#-#.# p = 63 tuberculin skin testing 63 mL kg 63 prior chemotherapy regimens 63 cells uL 63 mg kg dose 63 μg kg 63 Doxil ® 63 fatigue asthenia 63 Secondary endpoints included 63 virological response 63 prostate cancer CaP 63 PEG IFN 63 histologic subtype 63 TT genotype 63 noninferior 63 cyclophosphamide methotrexate 63 ACTEMRA TM 63 lopinavir r 63 perioperatively 63 intact parathyroid hormone 63 diabetes mellitus DM 63 postoperative complication 63 oral allopurinol 63 Acetate Rectal Suppositories 63 PREZISTA r 63 bronchioloalveolar carcinoma 63 BCG vaccinated 63 uM 63 Univariate analysis 63 idiopathic PAH 63 undergoing radical cystectomy 63 bioavailable testosterone 63 elevated ALT 63 free survival PFS 63 venlafaxine XR 63 serum testosterone 63 Kaplan Meier estimate 63 dalteparin 63 prior relapsers 63 achieved sustained virological 63 bladder carcinoma 63 undetectable PSA 63 remission CR 63 antiretroviral naive 63 neutropenic sepsis 63 ischemic lesions 63 mg eq 63 retrospective cohort 63 caspofungin 63 multivariate analyzes 63 endometrial carcinoma 63 titrated glipizide 63 microbiological eradication 63 mg BID dose 63 abdominal irradiation 63 IQR 63 serum urate levels 63 CrCl 63 LEXIVA r 63 polyp recurrence 63 oxycodone IR 63 lymphopenia 63 mg TID 63 bronchoalveolar lavage 63 malignant neoplasm 63 Kaplan Meier estimates 63 #OHD 63 μg ml 63 adenoma recurrence 63 total thyroidectomy 63 RECIST criteria 63 efavirenz EFV 63 imipenem 63 acute myeloid 63 salmeterol fluticasone propionate 63 ml kg 63 WOMAC pain 63 COPD exacerbation 63 mRCC 63 baseline CD4 63 evaluable 63 achieved statistical significance 63 tumor histology 63 Subgroup analysis 63 oblimersen 63 #mg/day [002] 63 IQR = 63 Baseline characteristics 63 pooled comparator 63 extracapsular extension 63 ribavirin RBV 63 #mg q8h 63 adefovir treated 63 severe exacerbations 63 Viread Emtriva Sustiva 63 β blockers 63 recurrent atrial fibrillation 63 ug ml 63 doxorubicin cyclophosphamide 63 cEVR 63 conjunctival hyperemia 63 normothermic 63 cells μL 63 mg tid 63 hepatic metastases 63 seroprotection 63 mg QD 63 nadolol 63 lamivudine refractory patients 63 TURBT 63 fluticasone salmeterol 63 undergone radical prostatectomy 63 elevated troponin 63 #.#mmol L [002] 63 methacholine challenge 63 5-fluorouracil/leucovorin 63 ug mL 63 ovarian carcinoma 63 arterial thromboembolic events 63 Postoperatively 63 mmol liter 63 nonpregnant 62 locoregional disease 62 Peg IFN 62 Pegylated Interferon 62 BRCA2 mutation carriers 62 elevated transaminases 62 aminotransferase elevations greater 62 microgram kg 62 Arch Intern Med 62 EBRT 62 vertebral fracture 62 mcg kg REBETOL 62 antiandrogen 62 interferon ribavirin 62 recurrent metastatic 62 cytoreduction 62 anaplastic astrocytomas 62 corticosteroid dose 62 HIV HCV coinfected 62 SUVmax 62 receiving highly emetogenic 62 FOLFOX6 62 dysuria 62 isoprostane 62 quetiapine risperidone 62 HOMA IR 62 hepatocellular carcinomas 62 highest quintile 62 FOLFIRI 62 asthma exacerbation 62 mg/m2 IV 62 underwent CABG 62 hemodynamically significant 62 nonvertebral fractures 62 mCRC patients 62 RLAI 62 ± SD 62 μg dL 62 #.#/# [005] 62 mg/m2/day 62 detrusor overactivity 62 Hb A1C 62 plasma uric acid 62 invasive aspergillosis 62 recurrent UTI 62 3mg/kg 62 desvenlafaxine succinate 62 perioperative complications 62 solifenacin 62 mEq L 62 homozygotes 62 nondiabetic 62 radioiodine therapy 62 nmol L. 62 VaD 62 PRADAXA #mg 62 symptomatic intracerebral hemorrhage 62 APTIVUS r 62 incontinence episodes 62 adriamycin 62 anthracycline taxane 62 chlamydial infection 62 #mg doses [002] 62 troponin T 62 x ULN 62 micafungin 62 dapagliflozin plus 62 nonexposed 62 mmHg p = 62 low dose Iluvien 62 mg simvastatin 62 mean baseline A1C 62 PCa 62 clinically localized prostate 62 mg m² 62 cTnI 62 periprocedural 62 undetectable viral 62 mitoxantrone chemotherapy 62 #-#,# mg 62 REMICADE monotherapy 62 leucopenia 62 plus aztreonam 62 renal cell carcinomas 62 #ug [002] 62 IFN alfa 62 recurrent acute pancreatitis 62 hepatitis C genotype 62 piperacillin tazobactam 62 metastatic malignant 62 univariate 62 NIHSS 62 Hazard Ratio = 62 Radical prostatectomy 62 monoinfected patients 62 liver transplant recipients 62 TAXUS p value 62 sustained virological response 62 postoperative chemotherapy 62 melphalan prednisone 62 Am J Cardiol 62 sero positive 62 #mmHg [001] 62 T1c 62 PROCTOCORT ® Suppository Hydrocortisone 62 ejection fractions 62 intestinal metaplasia 62 hemoglobin A1c levels 62 ASCUS 62 abacavir Ziagen 62 genotype 1b 62 ALT normalization 62 cilostazol 62 Hb A1c 62 ALT flares 62 serum prostate 62 Kaplan Meier method 62 KRAS wild 62 dacarbazine DTIC 62 laboratory abnormalities 62 serum cortisol 62 UGT#A# * 62 aspartate aminotransferase 62 virological failure 62 prospectively evaluated 62 estramustine 62 acromegalic patients 62 neutropaenia 62 adenotonsillectomy 62 invasive ductal 62 CANCIDAS 62 GOUT 62 mesalamine granules 62 HGPIN 62 intratympanic 62 intravesical therapy 62 underwent radical prostatectomy 62 anthracycline containing 62 mm Hg systolic 62 Secondary endpoints include 62 symptomatic VTE 62 #mg dose [002] 62 galiximab 62 mcg mL 62 radical prostatectomy RP 62 pyridostigmine 62 completely resected 62 ErbB2 positive 62 Montgomery Åsberg Depression 62 progesterone receptor negative 62 HDRS 62 mmol kg 62 antithymocyte globulin 62 hsCRP levels 62 chronic HCV genotype 62 bortezomib refractory 62 euthymic patients 62 multivariate Cox 62 HbA1c levels 62 vaginal hysterectomy 62 Zometa hazard 62 sensory neuropathy 62 prednisone prednisolone plus 62 debulking surgery 61 heterozygotes 61 atrophic gastritis 61 statistically significant p 61 confirmed CCyR 61 serum lipid levels 61 logistic regression model 61 μg doses 61 median CD4 61 TMC# r 61 mg d 61 pretest probability 61 HbA 1c 61 ACR Pedi 61 moderate renal impairment 61 IELT 61 CIMZIA ™ 61 epirubicin cyclophosphamide 61 receiving prophylactic anticoagulation 61 Breslow thickness 61 macroalbuminuria 61 idraparinux 61 XELOX 61 Rating Scale MADRS 61 mucosal inflammation 61 baseline FEV 61 anti HBs 61 -#.# mg dL [001] 61 kcal d 61 HbA1C 61 clomipramine 61 mg Androxal 61 tenecteplase 61 prospectively stratified 61 ACR# response 61 doxazosin 61 MIC# [001] 61 HBsAg 61 URTI 61 lipid lowering agents 61 splenectomized 61 NATRECOR R 61 β = 61 autoantibody positive 61 low dose cytarabine 61 hypogonadal 61 myelodysplastic myeloproliferative diseases 61 HPV-#/# 61 NIH CPSI 61 p = ns 61 LVEF 61 FDA defined valvulopathy 61 del 5q 61 CYP#D# inhibitor 61 smoldering myeloma 61 aspartate aminotransferase AST 61 attain statistical significance 61 NPH insulin 61 BRCA1 mutation carriers 61 neoadjuvant radiation 61 plus medroxyprogesterone acetate 61 lymphadenectomy 61 #q# deletion syndrome 61 SGRQ 61 singleton pregnancies 61 daily subcutaneous injections 61 Febrile neutropenia 61 IPAH 61 CLL SLL 61 care regimens CCR 61 metoprolol tartrate 61 mild renal insufficiency 61 external beam radiotherapy 61 acneform rash 61 nodal metastases 61 milliliters mL 61 noncarriers 61 saline placebo 61 HER2 expression 61 coinfected 61 attending antenatal clinics 61 hydroxyvitamin D levels 61 OAB symptoms 61 ng dl 61 indinavir 61 mCi m 2 61 corrected QT interval 61 mg kg Hematide 61 response pCR 61 Crohn Disease Activity 61 vincristine doxorubicin 61 male Sprague Dawley 61 hypokalemia 61 F FDG PET 61 serum TSH 61 echocardiographic parameters 61 Primary endpoints 61 achieved PASI 61 oral hypoglycemic agent 61 glycosylated hemoglobin HbA1c 61 tirofiban 61 urate lowering therapy 61 Score TOS 61 ethambutol 61 systolic BP 61 eosinophil count 61 urine albumin 61 alfa 2a 61 IIIa inhibitors 61 BMI ≥ 61 proband 61 male Wistar rats 61 FOLFOX 61 systolic dysfunction 61 RNA copies mL 61 relapsed ALL 61 pancreatic adenocarcinoma 61 FUSILEV enhances 61 complete cytogenetic 61 Pneumocystis carinii pneumonia 61 undetectable HCV RNA 61 thyroglobulin 61 visceral metastases 61 folinic acid 61 relapsed CLL 61 RGT arm 61 placebo p 61 #mg dosing group 61 normotensive 61 postoperative AF 61 VELCADE melphalan 61 trimethoprim sulfamethoxazole 61 BRCA mutation carriers 61 T1DM 61 colon rectal 61 undetectable viral load 61 #mg QD [002] 61 preoperatively 61 serum IGF 61 BUPHENYL R sodium phenylbutyrate 61 #ng/ml 61 nonischemic 61 epithelial ovarian cancer 61 urolithiasis 61 PaO 2 61 micrograms mL 61 neuropathy sensory 61 kg m² 61 recurrent genital herpes 61 Visual Analogue Scale VAS 61 cytarabine daunorubicin 61 nodular partial response 61 CVD mortality 61 TMP SMX 61 NRTI sparing 61 RBC transfusion 61 mutated KRAS 61 relapsers 61 endoscopic remission 61 Brief Psychiatric 61 fluorouracil leucovorin 61 cytogenetic responses 61 ATACAND 61 graft occlusion 61 rheumatoid factor 61 Elitek 61 cranial irradiation 61 hemodialysis patients 61 paclitaxel cisplatin 61 cytogenetic response 61 remission induction 61 nonvertebral fracture 61 #.#-#.# [011] 61 unresectable stage 61 dose cohort 61 distant metastases 61 papillary renal cell carcinoma 61 subcutaneous enoxaparin 61 adnexal mass 61 efficacy evaluable 61 dacarbazine chemotherapy 61 endometrial hyperplasia 61 androgen deprivation 61 cervicitis 61 ductal breast cancer 61 regression coefficient 61 prednisone prednisolone 61 proximal DVT 61 cisplatin vinorelbine 61 treatment naive genotype 61 oral diclofenac 61 collagenous colitis 61 mL sec 61 IU mL 61 seminal vesicle invasion 61 DAS# [002] 61 diameter stenosis 61 CDAI score 61 prevalences 61 placental malaria 61 ritonavir boosted 61 serum PSA 61 STELARA ® 61 plus gemcitabine 61 reflux esophagitis 61 transaminase elevations 61 SVR# 61 neovascular glaucoma 61 paclitaxel eluting stents 61 #μg [002] 61 tapentadol ER 60 radical nephrectomy 60 pamidronate 60 dyspareunia 60 glulisine 60 prospectively enrolled 60 GERD symptom 60 GG genotype 60 evaluable patients 60 mm3 60 nonpsychotic 60 CRu 60 Mg Uk 60 CDAI 60 sirolimus stent 60 neutrophil count 60 latent celiac disease 60 Response Evaluation Criteria 60 PegIFN RBV 60 acute cholecystitis 60 unresectable HCC 60 ng ml 60 Helicobacter pylori eradication 60 breast carcinoma 60 prostate cancer PCa 60 TAXUS Express Stent 60 BMI z 60 mcg doses 60 preterm neonates 60 clinically evaluable 60 adjuvant tamoxifen 60 pulmonary dysfunction 60 interleukin IL -6 60 enteroviral 60 atorvastatin #mg 60 parasitaemia 60 5FU 60 microalbumin test 60 undetectable virus HCV 60 albumin excretion 60 CYPHER Stent 60 fasting triglyceride levels 60 carboplatin paclitaxel 60 precancerous cervical 60 paricalcitol 60 Fasting plasma glucose 60 pancreatic resection 60 CK # plasma concentrations 60 ischemia driven 60 serum estradiol 60 depressive symptomatology 60 multivariable analyzes 60 neutropenic fever 60 logistic regression analyzes 60 postoperatively 60 pegylated interferon alpha 60 chronic HBV 60 #mg #mg #mg [003] 60 ß = 60 nutlin 3a 60 Adenomas 60 albumin excretion rate 60 HNSCC 60 titrated glipizide plus 60 metformin monotherapy 60 HIV RNA 60 gestational hypertension 60 ìg 60 paroxysmal AF 60 hemoglobin A1c HbA1c 60 seropositive patients 60 BMS p = 60 abnormal p# biomarker 60 Apidra ® 60 oral clodronate 60 RYGB 60 QALE 60 irinotecan chemotherapy 60 perimenopausal women 60 Plasma concentrations 60 XIENCE V demonstrated 60 μg dl 60 BENICAR HCT 60 dexamethasone Decadron 60 PPCM 60 pretreatment serum 60 Stent thrombosis 60 cervical intraepithelial neoplasia 60 overt hepatic encephalopathy HE 60 null responder 60 ALND 60 K#N 60 Cream USP 1 60 pg g 60 divalproex sodium 60 prostate carcinoma 60 subtrochanteric 60 HBeAg + 60 Myelodysplastic Syndrome MDS 60 mCi kg 60 LV ejection fraction 60 mCRPC 60 mechanically ventilated patients 60 plus prednisone 60 ACR# responses 60 Postoperative 60 FluCAM 60 Platelet counts 60 EGFR mutation positive 60 plasma folate 60 IFN α 60 #.#g/day 60 Kaplan Meier curves 60 del 5q MDS 60 Naive Patients 60 symptomatic intracranial hemorrhage 60 Infusion Reactions Severe 60 postoperative morbidity 60 Stage IIB 60 hMG 60 amisulpride 60 virologic failures 60 g dL 60 reintubation 60 perioperative mortality 60 atopic 60 localized renal 60 rebleeding 60 Adjuvant therapy 60 hemoglobin Hb 60 tenofovir emtricitabine 60 intraperitoneally 60 lobular cancer 60 BEACOPP 60 mg q#h 60 pretransplant 60 SSc 60 mg BID 60 CP CPPS 60 HCV genotype 60 daunorubicin 60 Non inferiority 60 IM progesterone 60 hyperphenylalaninemia HPA due 60 Peginterferon 60 serum aminotransferase levels

Back to home page